Shil Patel PhD

Shil Patel has 30 year industry experience following education and initial industry experience in CNS drug research at Merck in the UK. Subsequent transfer to Merck’s Imaging Group the US developing novel CNS PET ligands before setting up non-invasive imaging capabilities at Biogen for neurological drug R&D and then running the preclinical Imaging group at Eisai. Currently leading Imaging and Exploratory research at Codiak Biosciences in Cambridge MA.